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Introduction
T he current report presents examples of how medical re-search can contribute to the improvement of health care 
systems, especially in developing countries. We describe 
the Gastro-Esophageal Malignancies in Northern Iran (GEMINI) 
project, a group of related research studies originally designed to 
identify etiologic factors and prevention measures for upper gas-
trointestinal cancers in the Northern provinces of Iran. The suc-
cess of the GEMINI project shows the feasibility of large-scale 
scienti¿c studies in developing countries and the positive effects 
that such studies can have on both health research and the larger 
health care system of the country in which they have been per-
formed. 
The Caspian littoral of Iran is situated at the western end of the 
Central Asian Esophageal Cancer Belt, an area that extends from 
the Caspian Sea through Central Asia and Mongolia to northern 
China (Figure 1).1,2 In 1969, the population-based Caspian Cancer 
Registry was established in the northern provinces of Iran as a re-
sult of the joint efforts of Tehran University and the International 
Agency for Research on Cancer (IARC).3 This registry recorded 
esophageal cancer incidence rates up to 165/100,000 population/
year in men and 195/100,000 population/year in women, some of 
the highest incidence rates of esophageal cancer ever reported in 
the world.1–4
In addition to the Caspian Cancer Registry, preliminary ecologi-
cal and nutritional studies were conducted by IARC and Tehran 
University to establish the epidemiologic features and investigate 
the etiology of esophageal cancer throughout the Caspian litto-
ral.5,6 The results of these studies documented the role of some 
risk factors, especially poverty and very low consumption of fresh 
fruit and vegetables,6 factors that have been shown to be associ-
ated with increased risk of esophageal cancer in almost all coun-
tries.2 The role of other potential risk factors such as hot tea or nass 
consumption could not be fully assessed.5,6 Further investigations 
were discontinued in 1979 due to the sociopolitical changes in 
Iran, and the complete patterns of incidence and the full comple-
ment of risk factor results remained to be established. 
There also remained a need to obtain ongoing and accurate data 
on the burden and time trends of upper gastrointestinal cancers in 
northern Iran, as such data are essential for proper prioritization 
and budgeting of limited health care resources. Hence GEMINI 
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was launched in northern Iran to address these needs and also to 
¿nd an answer for questions that had remained unresolved for so 
many years. The following sections describe the development and 
achievements of this project. 
What has been done? 
In the late 1990s, new studies were launched to continue the 
evaluations of the earlier investigations. The ¿rst study was a 
1-year active surveillance of esophageal cancer which was car-
ried out from 1996 to 1997 in the Turkmen plain (now known 
as Golestan Province) at the southeastern corner of the Caspian 
Sea. In this study, the age-standardized incidence rates (ASR) of 
esophageal cancer were 144/100,000 in men and 49/100,000 in 
women.7 A second retrospective survey of all cancers in Goles-
tan Province in 1996-2000 reported esophageal cancer ASRs of 
43/100,000 in men and 36/100,000 in women.8 While lower than 
the incidence ¿gures in the 1970s, these rates were still among the 
highest reported in the world.2,8 With internal and international 
support, a new cancer registry was established in Iran in 1996, and 
this new cancer registry generated valuable data on the prevalence 
of all types of cancer in northern Iran. 9–14
Thereafter, in 1999, the idea of comprehensive studies of gastric 
and esophageal cancer in northern Iran was put forward by the 
Digestive Disease Research Center (DDRC), which is af¿liated 
with Tehran University of Medical Sciences (TUMS), and DDRC 
took the lead in the establishment of the GEMINI project. The aim 
of GEMINI was to investigate the etiology and genetics of upper 
gastrointestinal cancers in high-risk areas of Iran and to decrease 
the mortality and morbidity of these diseases by appropriate, tar-
geted preventive strategies.
At ¿rst, GEMINI consisted of several related projects, includ-
ing cancer registries in Golestan and Ardabil Provinces, initial de-
scriptive studies of epidemiologic features in the two provinces, 
and a case-control study of esophageal cancer in Golestan. Ard-
abil Province is located at the southwestern corner of the Caspian 
Sea, where the incidence of gastric cancer is one of the highest in 
the world and the incidence of esophageal cancer is moderate.13 
Results from these studies generated new hypotheses and provid-
ed the impetus to initiate a more comprehensive large prospective 
cohort study on upper gastrointestinal cancers in Golestan (Figure 
2). 
Before beginning GEMINI, agreement of governmental of-
¿cials and religious leaders was obtained, and Iranian faculty 
members from TUMS in relevant ¿elds of research were asked to 
participate in the project. Then an international network was cre-
ated. The principal investigators of the 1970s cancer registry were 
invited to take part in planning the project. Moreover, well-known 
international experts from the US National Cancer Institute (NCI) 
and IARC joined and supported the project from the beginning. 
This network prepared the ground to obtain internal and external 
funds for the preliminary phase of the project. A meeting of par-
ticipants held in IARC in 2000 was crucial in strengthening and 
integrating the network. Later on, scientists from several other in-
stitutions, including the University of Cambridge Cancer Genetics 
Group (UK), the Karolinska Institute (Sweden), the University of 
Glasgow (UK), the University of Leeds (UK), the Johns Hopkins 
University (US), Mount Sinai School of Medicine (US), and the 
University of Toronto (Canada) were involved in various aspects 
of the GEMINI project. 
The planning phase for GEMINI took two years (1999 to 2001), 
at the end of which two gastroenterology specialty clinics were es-
tablished in 2001: Atrak clinic in the city of Gonbad, in Golestan 
Province, and Aras clinic in the city of Ardabil, in Ardabil Prov-
ince. These two clinics were established with the dual purpose 
of improving the gastrointestinal health care services for the sur-
rounding populations and establishing permanent local bases for 
research studies. A U.S. federal-wide assurance (FWA00001331) 
was obtained for DDRC, followed by the establishment of an 
institutional review board (IRB) which was also registered 
(IRB00001641 DDRC) with the Of¿ce for Human Research Pro-
tections in the U.S. Department of Health and Human Services. 
Also in 2001, scientists at DDRC, NCI and IARC developed 
guidelines for the functioning of GEMINI. In general, each group 
was responsible for the phases of the project that were conducted 
in their own country, and all groups cooperated at every step in 
the design, conduct, and analysis of the project and in all result-
ing publications. DDRC was involved in data gathering through 
interviews and medical and endoscopic examinations, and also 
in the collection, storage, and transfer of hard data, electronic 
data, and biological samples. NCI and IARC were responsible 
for providing specialized laboratory assays in their countries and 
also for training DDRC researchers at their institutions. All parties 
were involved in providing methodological expertise. A Scienti¿c 
Committee composed of selected scientists from DDRC, NCI, 
IARC and other experts in this ¿eld was responsible for oversight 
of the project. 
Figure 1. The Central Asian Esophageal Cancer Belt (adopted 
from Kmet et al. 1972)1
Figure 2. Development of the GEMINI Research Project.  20(50): 7368 – 7374.
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Along with the development of collaborative networks and proj-
ect planning, initial studies were conducted to address some of the 
main questions that GEMINI investigators would face, including 
studies on the epidemiologic features of upper gastrointestinal 
cancers in northern Iran,15–18 the reliability and validity of opiate 
use self-report,19 the association of serum selenium levels and 
upper gastrointestinal cancers,20 genetic determinants of esopha-
geal cancer, 21–23  exposure to polycyclic aromatic hydrocarbons in 
the study population,24 and familial risk of esophageal cancer in 
Golestan.25
In 2001 to 2003 pilot studies were also conducted by DDRC, 
NCI and IARC to assess the feasibility and optimize methods for 
a case-control study of esophageal cancer in Golestan. The main 
aims of these studies were to optimize strategies for (a) data man-
agement and questionnaire design, (b) recruitment of all incident 
cases, (c) biological specimen collection/preservation, (d) clinic 
and population-based control selection, and (e) validation of labo-
ratory methods. 
Following these pilot studies, the Golestan Case-Control Study 
was conducted between 2003 and 2007 to compare demographic 
features and environmental exposures in esophageal cancer cases 
and controls in Golestan Province. In this study, designed jointly 
by DDRC, NCI and IARC, 300 cases of esophageal squamous 
cell carcinoma (ESCC), 300 clinic controls and 571 neighborhood 
controls were enrolled. Cases and age- and sex-matched clinic 
controls were recruited from patients who were referred to Atrak 
clinic for upper gastrointestinal symptoms. Cases had histology-
proven ESCC and controls had no esophageal dysplasia or cancer 
identi¿able by endoscopic examination. Another group of con-
trols, population-based neighborhood controls, were matched to 
cases for age, sex, and village or urban area of residence. Cases 
and clinic controls were interviewed and endoscoped at Atrak 
clinic, and biological specimens were collected including muco-
sal biopsies, blood, hair and nails. The neighborhood controls un-
derwent the same interview and blood, hair, and nails collection 
in their local health house or district health center. All samples 
were later transferred to Tehran. Environmental risk factors were 
assessed through detailed life-style and food frequency question-
naires that had been validated by pilot studies and through objec-
tive measurements in biological specimens from both cases and 
controls. The role of genetic polymorphisms was studied using 
genomic DNA from cases and controls, and these variants were 
matched with associated carcinogen data collected from question-
naires and carcinogen assays.
Results from the Golestan Case-Control Study have been dis-
seminated in papers examining several plausible risk factors for 
esophageal cancer, including opium, tobacco, and alcohol use,26 
poor oral hygiene,27 tea drinking habits,28 socio-economic deter-
minants,29 and exposure to polycyclic aromatic hydrocarbons.30 
This study continues to serve as a resource for testing other hy-
potheses.
At the same time that the case-control study began enrolling 
subjects, planning began for a large prospective cohort study in 
Golestan. The aims of this prospective cohort were: 1) to iden-
tify risk factors for upper gastrointestinal cancers; 2) to provide 
a sampling frame for nested case-control studies on upper gas-
trointestinal cancers; and 3) to provide a model for population-
based studies in a country in economic and social transition. The 
ultimate goal of the project was to study the dietary, life-style, 
anthropometric, ethnic, biochemical, and genetic determinants of 
upper gastro-intestinal cancers and to ¿nd an explanation for the 
high incidence of these types of cancer in northern Iran.
In 2003 and 2004, DDRC and Golestan University of Medical 
Sciences collaborated to establish the necessary infrastructure 
for the cohort study, built on the existing Primary Health Care 
(PHC) system in Golestan. The PHC system had originally been 
established to provide basic health care services and to improve 
reproductive health in remote rural areas in Iran,31 but it also has 
inherent capabilities for improving other health services and 
health research. In GEMINI, the PHC has evolved into a research-
oriented network. Adjuvant specialized referral centers were also 
established in the districts under study. 
Pilot studies for the cohort study were also performed, in col-
laboration with IARC and NCI. The aims of the studies were: to 
assess the response rate of the study population, to develop valid 
and reliable methods for data collection,19,32 to develop follow-up 
methods,33 to estimate the sample size and operating costs, and to 
evaluate the necessary logistics and human resources. Results of 
these studies con¿rmed the feasibility of launching a prospective 
cohort study in Golestan.34
In 2004, the Golestan Cohort Study (GCS) was launched.35 The 
sample size was based on disease incidence data derived from 
previous studies and over 50,000 subjects were recruited. Sub-
jects were selected using systematic cluster sampling from 3 main 
districts of Golestan. In rural areas, all residents of all villages 
in the study catchment area who were 40 to 75 years old, were 
apparently healthy, and were willing to participate in the study 
were invited. Temporary recruitment centers were established in 
the health houses of 198 selected villages, and the Behvarz (auxil-
iary health workers) accompanied the GCS research team to con-
tact the selected subjects at their homes. In urban areas, subjects 
were contacted at home by specially trained health workers and 
invited to visit the Golestan Cohort Study Center in Gonbad. Data 
collection was accomplished as expected. Biobanks with -80°C 
freezers and extra electricity and CO2 back-ups were established 
in Gonbad and Tehran. Because of the probability of natural disas-
ters such as earthquakes, which are frequent in Iran, all samples 
were divided into two sets, and one set was shipped to be stored 
in special conditions, including liquid nitrogen tanks, in the IARC 
biobank in Lyon, France. 
Enrollment in the Golestan Cohort Study was completed in 
2008. Since enrollment, all participants have been followed up 
actively every 12 months. Each cohort member has received a 
special membership card that facilitates their visit in Atrak clinic 
to explore upper gastrointestinal symptoms. Members were also 
instructed at the time of enrollment to contact the GCS team in 
case any unusual medical condition occurred, and these contacts 
are registered and subsequently followed up. The databases of 
Atrak Clinic and of the Golestan Cancer Registry are also re-
viewed monthly to look for cancer cases among the study sub-
jects. The follow-up is expected to continue for a minimum of 10 
years. As a result of recent developments in telecommunication 
and transportation, access of the majority of people to telephones 
and cell phones, adequate instruction of study subjects and active 
monitoring, loss to follow-up has been minimal (about 0.2%).35 
Mortality has been monitored and cause of death ascertained 
through available medical and hospital documents and, for those 
who die at home, verbal autopsy.33 Up to now, 2145 deaths have 
been recorded in the GCS, and the ¿rst series of papers on total 
and cause-speci¿c mortality and their risk factors has been pub-
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lished.36
Throughout its development, GEMINI has been supported ¿-
nancially by a combination of internal and external sources. The 
majority of the support has come from the Iranian government, 
both in direct grants and through the use of government-run facili-
ties (such as the Public Health Care system), but external grants, 
such as those available through IARC and Cancer Research UK, 
have also been obtained. These latter sources can also provide 
expertise to help organize and implement studies and infrastruc-
tures (such as cancer registries) that may be beyond the capacity 
of some developing countries. Dissemination and publication of 
results in international peer-reviewed journals has also been help-
ful in obtaining further ¿nancial support from both internal and 
external resources. 
What has been achieved?
Since the beginning of pilot studies in 2002, over 60 papers have 
been published on the results of the GEMINI project in medical 
journals indexed in the Institute for Scienti¿c Information (ISI) 
database. GEMINI studies have been successful in documenting 
cancer trends and investigating existing as well as new hypotheses 
for the etiology of upper gastrointestinal cancers. GEMINI stud-
ies have reported a 50% decline in esophageal cancer but no sig-
ni¿cant change in gastric cancer incidence in Golestan since the 
1970s.8 GEMINI studies in Ardabil have investigated the epide-
miology, anatomic distribution and histologic subtypes of gastric 
cancer,37,38 and studies in both Ardabil and Golestan have shown 
that about half of all gastric cancers in this region occur in the gas-
tric cardia.15 Ultimately, the results of the ongoing cancer registry 
have shown that between 2004 and 2008, the rate of esophageal 
cancer has declined while the rates of stomach, colorectal, and 
breast cancers are still increasing.39,40
GEMINI studies in Golestan have shown that self-report is a 
reliable and valid measure of opium use in this province,19 and 
that both opium and tobacco use are modest risk factors for ESCC 
in this population (odds ratios (OR) of 2.0 and 1.5, respectively).26 
However, these results may be different in case-control designs 
due to difference in the method of selecting controls41 Another 
study has shown that opium use increases the risk of both cardia 
and non-cardia gastric adenocarcinoma.42 They have also sug-
gested that dietary patterns may affect the risk of esophageal can-
cer43 and gastric cancer,44 and that prevalence of risk factors of 
esophageal cancer are not signi¿cantly different among various 
ethnicities in Golestan.45 They have demonstrated that drinking 
very hot tea (OR 8.2) is strongly associated with ESCC,28 that 
poor oral health increases risk of ESCC,27,46 and that several mea-
sures of low socioeconomic status are associated with this dis-
ease.29 Finally, they have shown that the Golestan population is 
highly exposed to polycyclic aromatic hydrocarbons (PAH),24,47,48 
and that PAH content in non-tumoral esophageal epithelial tissue 
(the target tissue for ESCC carcinogenesis) is dramatically higher 
in ESCC cases than in clinic controls (OR 26.6 for the 5th vs. 1st 
quintile of PAH content).30 Meanwhile, more recent studies have 
demonstrated genetic differences in PAH-related DNA adduct 
levels between female smokers and non-smokers in GCS.49
 GEMINI study also shows that among environmental risk fac-
tors, infections (including helicobacter pylori causing gastritis50 
and human papilloma virus51) may play an important roles in 
increasing risk of upper gastro-esophageal cancers. Results of 
another study suggest a synergistic effect between oral health 
and infection-induced atrophic gastritis in causing esophageal 
and gastric cancer, especially in the cardiac region.46 Studies in 
GCS are on the way to investigate the validity of this ¿nding and 
among them, one study has been designed to examine the role of 
animal contact in tranmission of bovine viruses.  
Some of the more recent studies have investigated the accuracy 
of diagnostic methods for screening gastro-intestinal diseases by 
using novel mathematical models. In the study that has been done 
based on the data of Golestan Case-Control Study, a new model 
has been devised for predicting the risk of esophageal squamous 
cell carcinoma and squamous dysplasia, which can be suitable for 
selecting high risk individuals and or increase the pretest probabil-
ity for screeing methods.52 This study has been exclusively done 
on environmental risk factors of cancer. More novel comprehen-
sive studies are on the way to examine the interaction between 
environmental, infectious, and genetic factors on cancers. 
GEMINI has also provided an excellent opportunity for study-
ing other non-communicable chronic diseases (NCDs), which 
based on WHO reports are raising ever more concerns in low- and 
middle-income countries,53,54 while reports still show that they are 
very often neglected in health care systems.55 Evidence shows that 
over 50% of mortalities are caused by NCDs and mainly by car-
diovascular diseases (CVDs), and the results of GCS study have 
supported this ¿nding.33 As the etiology of NCDs very much over-
laps with those of cancers, it would apparently be a cost-effective 
design to include NCDs among other outcomes of interest in GCS. 
As such, the data that has been collected on NCDs in GCS can be 
motives for policy makers in the health system to plan preven-
tive measures. Useful data has been gathered on cardiovascular 
disease (the most common cause of death in northern Iran), other 
cancers,9–14,56 cerebrovascular disease, diabetes mellitus,57 liver 
diseases and their risk factors,58–63 renal disease,64,65 and  obesity 
that are risk factors for several NCDs.66–68 
Finally, GEMINI should also be useful for early detection stud-
ies, cost-bene¿t analyses, and intervention studies for primary pre-
vention of NCDs.69 Numerous methods for primary prevention of 
NCDs are universally recognized (mostly lifestyle interventions), 
but their cost-effectiveness is not clearly known.70 Recently ¿xed-
dose combination therapy (the so-called polypill), composed of 
aspirin antihypertensives, and statins, has been suggested as a 
probable cost-effective intervention for preventing NCDs.71 Since 
2003, when the concept of Polypill was presented, few studies 
have been conducted to investigate the actual effect. A new meta-
analysis has suggested that Polypill can prevent large numbers of 
deaths due to ischemic heart disease (28,500) and stroke (12,700) 
in Iran.72 Even more amazing are the ¿ndings of several studies 
on the protective effects of low-dose aspirin in short- and long-
term cancer incidence (speci¿cally GI and hepatic cancers). 73–75 
and the bene¿ts of statins on preventing cancer-related mortal-
ity.76 Yet, the cost-effectiveness, feasibility, and acceptability of 
this prevention strategy remain to be investigated.
In this regard, DDRC decided to implement an interventional 
study (PolyIran) as one of the very few ¿rst studies on the dual 
effectiveness of Polypill on NCDs and cancers, using the infra-
structure that has been built in GCS. PolyIran is in fact the largest 
long-term cohort multiple randomized controlled trial (cmRCT) 
in the world, which is designed with adequate power to look for 
ef¿cacy of polypill.77 The pilot study of the safety and ef¿cacy 
of one polypill formulation and enrollment of 7,000 participants 
in GCS older than 50 years has been ¿nished and results will be 
Archives of Iranian Medicine, Volume 16, Number 1, January 201350
The Gastro-Esophageal Malignancies in Northern Iran 
published within the coming 3 years.78,79
In the course of GEMINI, tools for data collection have been 
tailored to the religious, ethical, social, and cultural background of 
inhabitants in Golestan and Ardabil. Several new research meth-
ods have been devised in GEMINI projects, including innovative 
methods to measure tea temperature,28 a sophisticated new com-
posite wealth score to estimate socio-economic status,29 a new 
method for verbal autopsy,33 innovative follow-up methods,35 and 
new methods for evaluation of target organ toxic exposures.30
The methods of data collection have also been designed in a way 
that makes the most of the existing health system. And the process 
of devising these tools and evaluating their accuracy in pilot stud-
ies can be an excellent model for other research projects wishing 
to ensure the reliability and validity of the data they gather.19,32
Another outcome of GEMINI is the introduction of new tech-
nologies to the health research system in Iran. Some of the labo-
ratory equipment has been imported and used in research for the 
¿rst time in Iran, and a new biobank of GEMINI biosamples has 
been established at DDRC for future genetic and molecular stud-
ies. These banked biosamples have great potential value for future 
‘-omics’ applications, including genomic, transcriptomic, pro-
teomic, and metabolomic studies. Other DDRC lab research ca-
pabilities, including DNA extraction, PCR, and serologic and mi-
crobiologic assays have also been upgraded. Furthermore, DDRC 
has been successful in taking advantage of advanced laboratory 
facilities at IARC and NCI as well. 
The local research infrastructure for GEMINI was largely built 
on the existing Primary Health Care (PHC) networks in Goles-
tan and Ardabil, but the introduction of GEMINI has also added 
valuable new resources to the local health care systems of these 
provinces. Establishment of cancer registries helps central evalu-
ation and planning for local health care needs, and the addition 
of new specialized health care centers, namely Atrak and Aras 
clinics, has expanded the capabilities and services of the local 
health care network.
GEMINI has also led to the formation of research networks 
within TUMS and with a larger national research network 
which includes TUMS, medical universities in Golestan and 
Ardabil, and other health institutes such as the Iran Blood 
Transfusion Organization Research Center, the Pasteur Insti-
tute, and the National Research Center for Genetic Engineer-
ing in Iran. Finally, GEMINI has facilitated the establishment 
of an international research network that includes members 
from some of the most well known health institutes from 
around the world. 
During the past decade, DDRC has also served as a model for 
the establishment of at least seven new gastroenterology research 
centers in medical universities all over Iran.80,81 Furthermore, the 
success of GEMINI has encouraged other research centers in Iran 
to launch cohort studies. For example, two cohort studies on dif-
ferent types of cancers have been started in Shiraz, in southern 
Iran, and in Tabriz, in northwestern Iran. In addition, another co-
hort study on ophthalmologic diseases has been launched in Shah-
rood, in central Iran. 
During the course of GEMINI, existing healthcare personnel 
were trained for accurate data collection. Additional staff were 
also recruited and trained. All of the internists and gastroenterolo-
gists in districts under study were involved and re-trained in spe-
cially designed Continuous Medical Education (CME) courses 
to further their talents in medical and endoscopic examinations. 
A large number of health assistants (Behvarz) in health houses, 
technicians, nurses, nutritionists, and general physicians were also 
trained in GEMINI. 
Several medical graduates were also given advanced training 
in areas related to research in gastroenterology, epidemiology, 
and biostatistics. Training was offered in both domestic and in-
ternational academic institutes. Overall, 12 gastroenterology fel-
lows ¿nished their post-doctoral training, 12 medical graduates 
attained MPH degrees, and 20 PhD candidates completed their 
doctoral studies. As a result of GEMINI’s achievements, DDRC 
was certi¿ed to begin a PhD degree program to enroll medical 
graduates who are interested in medical/epidemiologic research. 
Finally, faculty members in medical universities in Golestan 
and Ardabil as well as those in Shariati Hospital and other depart-
ments of TUMS and some other well-known research centers in 
Iran have been involved in GEMINI studies and have contributed 
to joint publications. 
As noted above, governmental of¿cials and religious lead-
ers have been consulted and informed at every step of the 
development of GEMINI, and this has enhanced the aware-
ness, interest and knowledge of these leaders in the results of 
GEMINI and its implications for the overall health care sys-
tem of Iran. GEMINI has clearly demonstrated the increasing 
importance of CVD and other chronic diseases for the health 
care system of the country, and the results of GEMINI have 
attracted the attention of the highest levels of the Ministry of 
Health towards the outbreak of chronic diseases in Iran. The 
results of GEMINI have also suggested that more energy of 
the health care delivery system should be focused on main-
taining the health of normal subjects (primary and secondary 
prevention of chronic disease), rather than concentrating all of 
the resources on disease treatment.
GEMINI has also changed the attitudes of many policy makers 
and academic faculty members and persuaded them that the ex-
isting health care infrastructure in the rural areas can be used ef-
¿ciently in health system research. In particular, policy makers in 
the Ministry of Health have been encouraged to devise procedures 
to expand research infrastructure and more accurately evaluate 
Iran’s health research system.
The principal investigators of GEMINI have made many speech-
es in medical universities and research institutes across Iran on the 
strategies and methods taken by DDRC in planning, launching, 
managing and reporting the GEMINI studies. The development of 
GEMINI and its achievements have also been presented at medi-
cal universities in Middle Eastern and North African countries 
such as Syria, Lebanon, Morocco and Tunisia, in Asian countries 
such as China, and in Western countries including the USA, Ger-
many, Italy, Canada, the UK and France. 
During the past 7 years, DDRC has obtained many national 
scienti¿c prizes in Iran (Avicenna, Razi, Hadavi, etc.), as well 
as prizes given directly by the President, the Governor of Tehran 
Province, and the Minister of Health. DDRC has also received 
the Best Research Paper Award from the Organisation of Islamic 
Cooperation’s Standing Committee on Scienti¿c and Technologi-
cal Cooperation in 2011. 
One of the main achievements of GEMINI at the regional and 
international level is that DDRC has been chosen as a World 
Health Organization (WHO) collaborating center for cancer re-
search in the Middle East and North Africa region for 2006 to 
2010 and again for 2011 to 2014.
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Conclusion
There are many reasons for the inadequacy of research evidence 
for appropriately directing health policies and health systems in 
developing countries.82 Although poor infrastructure, method-
ological challenges, and lack of consensus on guiding principles 
can be named among these reasons, “negative attitude” towards 
the “feasibility” of health research and its potential impact on 
health care is certainly one of the main barriers. Successful expe-
riences conducting research projects that have had considerable 
impact on health systems may be oases in a desert, but their mere 
existence proves their feasibility. 
Finally, well-designed research projects that provide a founda-
tion for scienti¿c collaboration among both developed and devel-
oping countries will achieve much more than their initial scienti¿c 
goals. In addition to the exchange of intellectual and scienti¿c ex-
pertise, such collaborations can also lead to the exchange of social 
and cultural capital between nations, despite the instability of po-
litical relationships between governments. 
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